Rick Suarez
Rick R. Suarez is Senior Vice President, US Market Access at AstraZeneca where he leads teams responsible for securing patient access to AstraZeneca medicines in collaboration with national and regional payers, distributors, retailers, wholesalers and Group Purchasing Organizations (GPOs). Rick’s teams are also responsible for reimbursement support through its internal hub, AstraZeneca Access 360, and one of the longest-standing patient assistance programs in the industry.
Rick has nearly two decades of diverse experience in healthcare leading teams aligned to Sales, Marketing, and Market Access, including heading up the NEXIUM franchise. Rick holds a BS in Chemistry and Sociology from the University of N. Alabama.
Rick brings unique perspective on the external environment and the move towards greater focus on value-based payment. Under Rick’s leadership, AstraZeneca has emerged as an industry leader in value-based agreements.
Rick R. Suarez is Senior Vice President, US Market Access at AstraZeneca where he leads teams responsible for securing patient access to AstraZeneca medicines in collaboration with national and regional payers, distributors, retailers, wholesalers and Group Purchasing Organizations (GPOs). Rick’s teams are also responsible for reimbursement support through its internal hub, AstraZeneca Access 360, and one of the longest-standing patient assistance programs in the industry.
Rick has nearly two decades of diverse experience in healthcare leading teams aligned to Sales, Marketing, and Market Access, including heading up the NEXIUM franchise. Rick holds a BS in Chemistry and Sociology from the University of N. Alabama.
Rick brings unique perspective on the external environment and the move towards greater focus on value-based payment. Under Rick’s leadership, AstraZeneca has emerged as an industry leader in value-based agreements.
Articles: Rick Suarez
Three Basic Truths About the US Healthcare System
USA / AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward. Discussion and debate related to cost and quality in healthcare has never been more pronounced or more contentious, whether focusing on medicines, healthcare services, providers or…
Latest Report
